Equities analysts predict that ArQule, Inc. (NASDAQ:ARQL) will announce earnings of ($0.06) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for ArQule’s earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.05). ArQule reported earnings per share of ($0.11) in the same quarter last year, which suggests a positive year-over-year growth rate of 45.5%. The company is expected to report its next quarterly earnings report on Wednesday, May 2nd.

On average, analysts expect that ArQule will report full-year earnings of ($0.32) per share for the current fiscal year. For the next year, analysts expect that the company will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.35) to ($0.34). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover ArQule.

How to Become a New Pot Stock Millionaire

ArQule (NASDAQ:ARQL) last announced its quarterly earnings data on Monday, March 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.09). During the same quarter last year, the business earned ($0.10) earnings per share.

Several equities research analysts recently commented on ARQL shares. Roth Capital started coverage on shares of ArQule in a research note on Thursday, February 22nd. They set a “buy” rating and a $5.00 price target on the stock. B. Riley set a $3.00 price target on shares of ArQule and gave the stock a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research upgraded shares of ArQule from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research note on Tuesday. ValuEngine upgraded shares of ArQule from a “sell” rating to a “hold” rating in a research note on Thursday, March 15th. Finally, Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $3.50.

Shares of ArQule stock traded up $0.44 during trading hours on Friday, reaching $2.87. 2,456,886 shares of the company traded hands, compared to its average volume of 371,308. ArQule has a 12-month low of $0.92 and a 12-month high of $2.94. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.98 and a quick ratio of 4.98. The firm has a market cap of $202.10, a price-to-earnings ratio of -7.36 and a beta of 1.43.

Large investors have recently made changes to their positions in the stock. Millennium Management LLC acquired a new position in ArQule in the fourth quarter valued at $165,000. Northern Trust Corp increased its stake in ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 1,385 shares during the period. Virtu Financial LLC increased its stake in ArQule by 343.8% in the fourth quarter. Virtu Financial LLC now owns 129,038 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 99,964 shares during the period. Deutsche Bank AG purchased a new stake in shares of ArQule in the fourth quarter valued at about $390,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of ArQule in the third quarter valued at about $2,220,000. Hedge funds and other institutional investors own 67.05% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/arqule-inc-arql-expected-to-post-earnings-of-0-06-per-share/1954419.html.

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.